MOLM-13 AML cells were treated with either SBI-4668 at 3, 10, or 30 μM or with RMC-4550, a highly potent SHP099-like SHP2 allosteric inhibitor (11), for 3 or 24 h, and p-ERK1/2 levels were detected by immunoblot analysis (Fig. 4E). Here, PTPN11 is linked to acute myeloid leukemia.